argenx SE (ARGX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong product development, market expansion, and positive feedback on VYVGART. Despite some uncertainties, the optimistic guidance, strategic pipeline expansion, and growing market penetration suggest a positive outlook. The Q&A session reinforces confidence in product growth and market strategy, with promising updates on trials and potential new indications. However, some management responses were vague, which could temper enthusiasm slightly. Overall, the sentiment leans positive, with potential for stock price appreciation in the short term.
Key Financial Performance
Total product net sales $1.13 billion in Q3 2025, marking a 96% year-over-year growth ($554 million increase). The growth is attributed to the strong performance of VYVGART, particularly in the U.S. market, and the successful launch of the prefilled syringe (PFS).
Product net sales in the U.S. $964 million in Q3 2025, a 20% quarter-over-quarter growth. This growth reflects the impact of investments in the PFS launch earlier this year.
Operating expenses $805 million in Q3 2025, a 5% increase compared to Q2 2025. R&D expenses increased by 9% ($28 million), and SG&A expenses increased by 4% ($11 million). The increase is due to continued investments in growth opportunities.
Operating profit $346 million in Q3 2025. This reflects strong revenue performance and disciplined expense management.
Profit before tax $386 million in Q3 2025. This includes a quarterly financial income of $43 million.
Profit after tax $344 million in Q3 2025, with a year-to-date effective tax rate of 13%.
Cash balance $4.3 billion at the end of Q3 2025, representing a nearly $1 billion increase since the beginning of the year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VYVGART: Delivering impact in 2 blockbuster indications (MG and CIDP). Prefilled syringe approved in most major markets, driving new patient and prescriber adoption.
Pipeline Progress: Entering 2026 with 3 Phase III assets and 4 new molecules in Phase I development by year-end.
Empasiprubart: Now in Phase III development for MMN and CIDP, targeting autoimmune diseases with a selective approach.
ARGX-119: Advanced to Phase III in CMS, designed to restore neuromuscular junction function, with potential applications in ALS and SMA.
U.S. Market: Product net sales of $964 million in the U.S., reflecting a 20% quarter-over-quarter growth.
Global Expansion: PFS approved in most major markets, driving growth outside the U.S. with $94 million in sales across rest of the world markets.
Payer Access: Strengthened payer access, enabling more patients to initiate treatment.
Manufacturing Expansion: Expanded collaboration with FUJIFILM through a new manufacturing facility in North Carolina to strengthen global supply chain.
Financial Performance: Achieved $1.13 billion in total product net sales in Q3 2025, marking a 19% growth from the previous quarter and 96% year-over-year growth.
Cost Management: Operating expenses increased by 5% compared to the previous quarter, with combined R&D and SG&A expenses expected to land between $2.6 billion and $2.7 billion for the year.
Vision 2030: Focused on long-term value creation with investments in pipeline innovation and scaling operations.
Indication Prioritization: Stopped development of empasiprubart in dermatomyositis and efgartigimod in lupus nephritis to focus on high-value indications like Graves' disease.
Future Growth: Preparing for 5 registrational readouts in 2026, including Ocular MG, Myositis, TED, MMN, and ITP.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Operational challenges in study enrollment: The company faced operational challenges in enrolling participants for the empasiprubart study in dermatomyositis, leading to the decision to stop development in this indication.
Decision not to advance efgartigimod in lupus nephritis: Based on Phase II data, the company decided not to proceed with a registrational study for efgartigimod in lupus nephritis, indicating potential limitations in efficacy or strategic prioritization.
Scaling operations and supply chain risks: The company is expanding its operations in the U.S., including a new manufacturing facility in North Carolina. This expansion could pose risks related to scaling operations and ensuring a robust global supply chain.
Regulatory and clinical trial risks: The company has multiple Phase III readouts planned, and any unfavorable outcomes could impact its strategic objectives and market potential.
Market competition and adoption challenges: While VYVGART is performing well, the company faces competitive pressures to maintain its leadership in MG and CIDP, especially as it seeks to expand into new indications.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Vision 2030: The company has set a bold growth agenda anchored in its long-term roadmap for value creation, Vision 2030, which includes multiple pathways for sustained growth and long-term value for patients and shareholders.
VYVGART Expansion: Plans to file for a label expansion for VYVGART to include all three seronegative subgroups (MuSK-positive, LRP4 positive, and triple seronegative) based on positive clinical data.
Phase III Developments: The company will enter 2026 with three Phase III assets: efgartigimod, empasiprubart, and ARGX-119, each representing significant opportunities in autoimmune and neuromuscular diseases.
New Molecules and Pipeline: Four new molecules are expected to enter Phase I development by year-end, with more expected to advance from 20 active IIP programs, representing potential breakthroughs in immunology.
Graves' Disease Study: Plans to initiate registrational studies for Graves' disease early next year, moving directly into Phase III.
Registrational Readouts: Five registrational readouts are expected next year, including Ocular MG, Myositis, TED, MMN, and ITP, each with strong commercial potential and robust clinical endpoints.
Manufacturing Expansion: Expanded collaboration with FUJIFILM through a new manufacturing facility in North Carolina to strengthen the global supply chain and meet growing demand for VYVGART and future pipeline therapies.
Rheumatology and Endocrinology Expansion: Plans to expand into rheumatology and endocrinology with myositis and TED studies, leveraging strong biologic rationale and clinical data.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you confirm if all three formulations of VYVGART are contributing to growth in CIDP and MG, and provide perspectives on Sjogren's disease?
A:Yes, all three formulations of VYVGART are contributing to growth, with the prefilled syringe being the major driver. For Sjogren's disease, Novartis' data showed a statistically significant win, but there is room for improvement. VYVGART is believed to target circulating immune complexes more precisely than broad B-cell suppression.
Q:What feedback are you receiving about the CIDP launch and efforts to make efgart a first-line option?
A:Feedback has been positive, with real-world experience reflecting clinical trial results in efficacy and safety. Early experience shows 85% of patients are IVIg switch patients, but there is also growth in naive patients. The prescriber base is expanding, and there is momentum for market penetration across all patient segments.
Q:What is the revenue potential for VYVGART's pivotal readouts in 2026, and why pursue Graves' disease?
A:Each Phase III indication represents an MG-like revenue opportunity. Graves' disease has a clear biology rationale and unmet medical need, with a subset of patients not responding to current medications. VYVGART could provide an alternative for these patients.
Q:Why was empasiprubart discontinued in DM, and what is the status of CIDP empasiprubart enrollment?
A:Empasiprubart was discontinued in DM due to competitive enrollment issues and high inclusion criteria. CIDP empasiprubart trials have just started, so enrollment projections are too early to assess.
Q:What are the expectations for thyroid eye disease (TED) studies and their relation to Graves' disease?
A:Positioning for TED will depend on trial data. TED and Graves' disease share the same underlying biology, and efforts in Graves' disease increase focus on the thyroid space. There is room for improvement in efficacy and safety.
Q:Can you provide updates on ARGX-121 and 213, and the growth drivers for VYVGART sales?
A:ARGX-121 and 213 are progressing through Phase I studies, focusing on safety, tolerability, and PD effects. VYVGART sales growth is driven by both MG and CIDP, with MG being the #1 biologic brand and CIDP showing market share expansion.
Q:What is the confidence in the seronegative MG opportunity and MSE data findings?
A:The SELON study showed a significant reduction in MG-ADL scores, with benefits accruing over cycles. Confidence is high in addressing the unmet need for seronegative MG patients. More MSE data will be disclosed in the future.
Q:What is the bar for success in myositis trials, and how is the steroid tapering protocol being integrated?
A:Success is defined as statistically significant separation from placebo, with a TIS of 20 considered clinically meaningful. The Phase II data showed increasing benefits with higher TIS thresholds. The steroid tapering protocol aims to mitigate placebo risk.
Q:Why was the endpoint changed for the EMPASSION trial in MMN, and what is the new endpoint?
A:The endpoint was changed to group strength in consultation with agencies, as it has a precedent and strong Phase II data support. The change does not affect the probability of showing benefit.
Q:What insights can be drawn from lupus nephritis data for future indication selection?
A:The lupus nephritis data do not support a registrational study but may inform decisions for other assets in the portfolio.
Q:Does the ianalumab data in Sjogren's disease align with expectations for the UNITY study?
A:Yes, the placebo effect in ianalumab data aligns with historical trials and expectations for the UNITY study.
Q:What are your thoughts on J&J's head-to-head trial for Imaavy versus VYVGART in gMG?
A:The trial may not provide significant new information, as it focuses on PD effects rather than real-world usage. VYVGART's long-term data show sustained MSE, and the competitive landscape remains unchanged.
Q:What is the strategy for external innovation with the $4.3 billion balance sheet?
A:The focus is on novel biology, expanding the hunting ground to include young biotech companies while maintaining collaboration with academic labs.
Q:What is the patient growth trajectory for VYVGART, and when will patient adds peak?
A:Patient growth is consistent across MG and CIDP, with new prescribers contributing to growth. The growth curve is still in its early stages, and patient adds are expected to continue.
Q:What is the progress in ex-U.S. launches for VYVGART?
A:Japan shows strong demand growth for MG and CIDP. In Europe and Canada, pricing and reimbursement agreements are in place, with CIDP launches expanding in additional markets.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the trial design for Graves' disease, the rationale for triple seronegative MG patients' lower responsiveness, and the exact patient numbers for VYVGART therapy. Additionally, they did not comment on the potential disease modification in Graves' disease or the competitive landscape for TED.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALKIVIA study
CEO Executive
Co Founder
DM
Executive Director
Founder CEO
III development
MuSK
Phase III
Today
adoption
autoantibody disease
biology
challenge
commitment population
day
demand patient
door
engagement
flexibility
immunology
improvement ADL
indication product
label expansion
launch PFS
market momentum
market patient
molecule Phase
need patient
neurology
rationale
reach
score
steroid reduction
story patient
subgroup
syringe demand
tax date
treatment option
ARGX Transcript
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
argenx SE (ARGX) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary indicates strong financial performance with a 25% revenue increase and a shift from net loss to net income. Cash reserves are robust at $1.5 billion. Despite increased R&D and operating expenses, the financial health appears stable, supporting growth initiatives. The absence of strategic, operational, and risk updates in the call limits insights, but the positive financial results and cash position suggest a positive market reaction over the next two weeks.
argenx SE (ARGX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary and Q&A indicate strong financial performance, a robust pipeline with significant growth potential, and strategic expansions. Positive clinical data and label expansions for VYVGART, along with a growing addressable market, are promising. While management was unclear on some specifics, the overall sentiment remains positive due to the company's strategic initiatives and expected growth across multiple fronts.
ARGX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
